Biostage, Inc. Common Stock
BSTG
BSTG was delisted on the 5th of October, 2017.
29 hedge funds and large institutions have $3.27M invested in Biostage, Inc. Common Stock in 2016 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 3 increasing their positions, 8 reducing their positions, and 4 closing their positions.
150% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 4
26% more funds holding
Funds holding: 23 → 29 (+6)
63% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 8
94% less capital invested
Capital invested by funds: $52.7M → $3.27M (-$49.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$1.05M |
| 2 |
State of New Jersey Common Pension Fund D
Trenton,
New Jersey
|
+$169K |
| 3 |
California Public Employees Retirement System
Sacramento,
California
|
+$105K |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$43.1K |
| 5 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
+$18.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$79K |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
-$47K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$32K |
| 4 |
PM
Penbrook Management
New York
|
-$8.31K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$4.61K |
BSTG Hedge Fund Activity: Q2 2016 in Review
29 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in Biostage, Inc. Common Stock (BSTG) for Q2 2016, worth a combined $3.27M — down 94% from $52.7M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new BSTG positions and 4 closed out — a net gain of 6 holders — while 3 added to existing stakes and 8 trimmed.
The largest buyer was Anson Funds Management, opening a new position worth an estimated $1.05M. The largest seller was Renaissance Technologies, cutting an estimated $79K.
- 29 institutional investors held Biostage, Inc. Common Stock (BSTG) as of Q2 2016, up from 23 in Q1 2016.
- Funds reported $3.27M of Biostage, Inc. Common Stock stock for Q2 2016, down 94% quarter-over-quarter.
- 10 funds opened new Biostage, Inc. Common Stock positions in Q2 2016 and 4 closed out, a net change of +6 holders.
- The largest Biostage, Inc. Common Stock buyer in Q2 2016 was Anson Funds Management, an estimated $1.05M added.
- The largest Biostage, Inc. Common Stock seller in Q2 2016 was Renaissance Technologies, an estimated $79K sold.
Based on aggregated 13F filings for Q2 2016.